Demographics and baseline characteristics
| Intervention (n=29) | Comparison (n=29) | |
| Age | 38±13 | 38±15 |
| Female, n (%) | 28 (97) | 27 (93) |
| White, n (%) | 28 (97) | 25 (86) |
| Body mass index (kg/m²) | 25.90±6.26 | 24.84±5.09 |
| Adequate Relief | 0.14±0.36 | 0.21±0.41 |
| Global Improvement Scale (GIS) | −0.29±1.21 | 0.17±0.76 |
| Symptom Severity Scale (SSS) | 269±68 | 261±91 |
| Quality of Life (QOL) | 39±17 | 42±19 |
| Taking medications for IBS, n (%) | 6 (21) | 2 (7) |
| Taking antidepressants, n (%) | 6 (21) | 7 (24) |
| IBS subtype15 | ||
| IBS-C (n) | 4 | 6 |
| IBS-D (n) | 3 | 4 |
| IBS-M (n) | 4 | 9 |
| IBS-U (n) | 18 | 10 |
All values are mean±SD, unless otherwise noted. Baseline differences in means were assessed with t-tests for quality of life, SSS and body mass index, while differences in distributions of GIS were determined by Wilcoxon rank-sum testing.
IBS, irritable bowel syndrome; IBS-C, IBS with constipation; IBS-D, IBS with diarrhoea; IBS-M, mixed IBS; IBS-U, unsubtyped IBS.